GSK, the manufacturer of the antibody-drug conjugate belantamab mafodotin-blmf (Blenrep), has announced positive top-line findings from the phase 3 DREAMM-8 trial for belantamab mafodotin combined with pomalidomide and dexamethasone in treating relapsed/refractory multiple myeloma. The trial, which involved about 450 patients, met its primary endpoint of improved progression-free survival (PFS) and showed a favorable trend in overall survival (OS) compared to the standard bortezomib with pomalidomide and dexamethasone regimen.

The open-label, multicenter study required patients to have undergone at least one prior line of treatment, including a lenalidomide-containing regimen. Patients were randomized to receive either the investigational combination or the standard care, with the study focusing on PFS and other secondary outcomes like OS and safety. Previously, the DREAMM-7 trial had shown significant PFS improvement with belantamab mafodotin and bortezomib over a daratumumab-based regimen, especially in lenalidomide-refractory and high-risk cytogenetic patients.

Reference: Doherty K. DREAMM-8 Produces Positive Topline Results in Relapsed/Refractory Multiple Myeloma. OncLive. Updated March 7, 2024. Accessed April 5, 2024. https://www.onclive.com/view/dreamm-8-produces-positive-headline-results-in-relapsed-refractory-multiple-myeloma